Wu et al. conducted a phase III RCT and suggested that first-line erlotinib can significantly improve PFS as compared to gemcitabine+cisplatin in patients with EGFR mutation–positive NSCLC [59]. Here, EGFR is linked to non-small cell lung carcinoma.